Excess mortality for patients with residual disease following resection of pituitary adenomas

Pituitary

Volumn 14, Issue 3, 2011, Pages 276-283

  Sughrue, Michael E ^a   Chang, Edward F ^a   Gabriel, Rodney A ^a   Aghi, Manish K ^a   Blevins, Lewis S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mortality; Pituitary tumors

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ACTH SECRETING ADENOMA; ARTICLE; CANCER MORTALITY; CUSHING DISEASE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS ADENOMA; META ANALYSIS; MINIMAL RESIDUAL DISEASE; NONFUNCTIONING PITUITARY ADENOMA; PRIORITY JOURNAL; PROLACTINOMA; STANDARDIZED MORTALITY RATIO; SURGICAL MORTALITY; THYROTROPIN SECRETING ADENOMA; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ACTH-SECRETING PITUITARY ADENOMA; GROWTH HORMONE; HUMANS; PITUITARY NEOPLASMS;

EID: 80053895272     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0308-1     Document Type: Article

References (59)

1. Levy A, Lightman S (2003) Molecular defects in the pathogen-esis of pituitary tumours. Front Neuroendocrinol 24(2):94-127 (Pubitemid 36581937)
2. Melmed S (2008) Update in pituitary disease. J Clin Endocrinol Metab 93(2):331-338 (Pubitemid 351240799)
3. Chang EF, Sughrue ME, Zada G, Wilson CB, Blevins LS Jr, Kunwar S (2010) Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas. Pituitary 13(3):223-229
4. Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Blevins LS Jr (2009) Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary 12(3):158-164
5. DerSimonian R (1990) Combining evidence from clinical trials. Anesth Analg 70(5):475-476 (Pubitemid 20249168)
6. Der Simonian R (1996) Meta-analysis in the design and monitoring of clinical trials. Stat Med 15(12):1237-1248 discussion 1249-1252
7. Der Simonian R, Charette LJ, McPeek B, Mosteller F (1982) Reporting on methods in clinical trials. N Engl J Med 306(22): 1332-1337 (Pubitemid 12105160)
8. Der Simonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188 (Pubitemid 17189972)
9. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83(10):3411-3418 (Pubitemid 28500865)
10. Arita K, Kurisu K, Tominaga A et al (2003) Mortality in 154 surgically treated patients with acromegaly: a 10-year follow-up survey. Endocr J 50(2):163-172 (Pubitemid 36554107)
11. Bates AS, Van't Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86(5):293-299 (Pubitemid 23160830)
12. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 58(1):86-91 (Pubitemid 36098853)
13. Biermasz NR, Dekker FW, Pereira AM et al (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89(6):2789-2796 (Pubitemid 38766367)
14. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667-674 (Pubitemid 38269875)
15. Kauppinen-Makelin R, Sane T, Reunanen A et al (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7):4081-4086 (Pubitemid 41058176)
16. Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. UK acromegaly study group. J Clin Endocrinol Metab 83(8):2730-2734 (Pubitemid 28493768)
17. Swearingen B, Barker FG II, Katznelson L et al (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83(10): 3419-3426 (Pubitemid 28500866)
18. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER (2005) Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir 147(3):243-251 discussion 250-241
19. Dekkers OM, Biermasz NR, Pereira AM et al (2007) Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92(3):976-981 (Pubitemid 46465672)
20. Hammer GD, Tyrrell JB, Lamborn KR et al (2004) Transsphe-noidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 89(12):6348-6357 (Pubitemid 39628458)
21. Lindholm J, Nielsen EH, Bjerre P et al (2006) Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol 65(1):51-58
22. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89(4):1613-1617 (Pubitemid 38507910)
23. Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol 40(4): 479-484 (Pubitemid 24194645)
24. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 41(1):95-102 (Pubitemid 24232533)
25. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B (1988) Epidemiology, long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223(4):327-335
26. Mestron A, Webb SM, Astorga R et al (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4): 439-446 (Pubitemid 39430260)
27. Bihan H, Espinosa C, Valdes-Socin H et al (2004) Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 89(11):5308-5313 (Pubitemid 39518402)
28. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89-95
29. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 12(1):71-79 (Pubitemid 10174985)
30. Nabarro JD (1987) Acromegaly. Clin Endocrinol 26(4):481-512 (Pubitemid 17036415)
31. Welbourn RB (1985) Survival and causes of death after adre-nalectomy for Cushing's disease. Surgery 97(1):16-20 (Pubitemid 15244871)
32. Watson RG, van Heerden JA, Northcutt RC, Grant CS, Ilstrup DM (1986) Results of adrenal surgery for Cushing's syndrome: 10 years experience. World J Surg 10(4):531-538 (Pubitemid 16096408)
33. Grabner P, Hauer-Jensen M, Jervell J, Flatmark A (1991) Long-term results of treatment of Cushing's disease by adrenalectomy. Eur J Surg 157(8):461-464
34. Favia G, Boscaro M, Lumachi F, D'Amico DF (1994) Role of bilateral adrenalectomy in Cushing's disease. World J Surg 18(4):462-466 (Pubitemid 24273841)
35. Hoybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL (2001) Adrenocorticotropic hormone-producing pituitary tumors: 12-22-year follow-up after treatment with ste-reotactic radiosurgery. Neurosurgery 49(2):284-291 discussion 291-282
36. Kobayashi T, Kida Y, Mori Y (2002) Gamma knife radiosurgery in the treatment of Cushing's disease: long-term results. J Neu-rosurg 97(5 Suppl):422-428 (Pubitemid 35424317)
37. Nagesser SK, van Seters AP, Kievit J et al (2000) Treatment of pituitary-dependent Cushing's syndrome: long-term results of unilateral adrenalectomy followed by external pituitary irradiation compared to transsphenoidal pituitary surgery. Clin Endo-crinol 52(4):427-435 (Pubitemid 30249810)
38. Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr (2000) Radiosurgery for Cushing's disease after failed trans-sphenoidal surgery. J Neurosurg 93(5):738-742 (Pubitemid 32803394)
39. Swearingen B, Biller BM, Barker FG II et al (1999) Long-term mortality after transsphenoidal surgery for Cushing's disease. Ann Intern Med 130(10):821-824 (Pubitemid 29231150)
40. Pikkarainen L, Sane T, Reunanen A (1999) The survival and well-being of patients treated for Cushing's syndrome. J Intern Med 245(5):463-468 (Pubitemid 29232235)
41. Barker FG II, Klibanski A, Swearingen B (2003) Transsphenoidal surgery for pituitary tumors in the US, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88(10):4709-4719 (Pubitemid 37357516)
42. Chang EF, Zada G, Kim S et al (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108(4):736-745 (Pubitemid 351498969)
43. Tomlinson JW, Holden N, Hills RK et al (2001) Association between premature mortality and hypopituitarism. West midlands prospective hypopituitary study group. Lancet 357(9254): 425-431 (Pubitemid 32156141)
44. Bates AS, Bullivant B, Sheppard MC, Stewart PM (1999) Life expectancy following surgery for pituitary tumours. Clin Endo-crinol 50(3):315-319 (Pubitemid 29166710)
45. Sanno N, Teramoto A, Osamura RY (2000) Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg 93(2):194-200 (Pubitemid 30604859)
46. Teramoto A, Sanno N, Tahara S, Osamura YR (2004) Pathological study of thyrotropin-secreting pituitary adenoma: pluri-hormonality and medical treatment. Acta Neuropathol 108(2): 147-153 (Pubitemid 39136301)
47. Beck-Peccoz P, Persani L (2006) TSH-induced hyperthyroidism caused by a pituitary tumor. Nat Clin Pract Endocrinol Metab 2(9):524-528 quiz following p 528 (Pubitemid 44353293)
48. Sanno N, Teramoto A, Osamura RY (2001) Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment. J Neurooncol 54(2):179-186 (Pubitemid 33089250)
49. Chanson P, Weintraub BD, Harris AG (1993) Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119(3):236-240 (Pubitemid 23327625)
50. Caron P, Arlot S, Bauters C et al (2001) Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 86(6):2849-2853 (Pubitemid 32545750)
51. Kuhn JM, Arlot S, Lefebvre H et al (2000) Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 85(4):1487-1491 (Pubitemid 32289490)
52. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P (1996) Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 81(8):3084-3090 (Pubitemid 26323913)
53. Socin HV, Chanson P, Delemer B et al (2003) The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148(4):433-442 (Pubitemid 36527414)
54. Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD (1999) Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 84(2):476-486 (Pubitemid 29075672)
55. Gesundheit N, Petrick PA, Nissim M et al (1989) Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of 9 patients. Ann Intern Med 111(10):827-835 (Pubitemid 19283919)
56. McCutcheon IE, Weintraub BD, Oldfield EH (1990) Surgical treatment of thyrotropin-secreting pituitary adenomas. J Neuro-surg 73(5):674-683 (Pubitemid 20364481)
57. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM (1994) Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 40(3):421-428 (Pubitemid 24194639)
58. Hankinson SE, Willett WC, Michaud DS et al (1999) Plasma prolactin levels and subsequent risk of breast cancer in post-menopausal women. J Natl Cancer Inst 91(7):629-634 (Pubitemid 29194050)
59. Clayton RN, Stewart PM, Shalet SM, Wass JA (1999) Pituitary surgery for acromegaly. Should be done by specialists. BMJ 319(7210):588-589 (Pubitemid 29414550)